Sodium‐glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: Systematic review

By Rasalam R, Atherton JJ, Deed G, et al
Published July 6, 2021

Key Takeaways

Researchers investigated how sodium–glucose cotransporter 2 inhibitors (SGLT2is) impact hospitalization for heart failure (HHF) and cardiac structure/function, by analyzing relevant randomized controlled trials (RCTs). They also intended to explore RCT-derived evidence for SGLT2i efficacy mechanisms in heart failure. They searched Medline and Embase. Findings revealed that a decrease in HHF was conferred by SGLT2is, irrespective of type-2 diabetes mellitus status, and a possible contributor to this efficacy was reversal of adverse left ventricular remodelling. Hypothesis-driven mechanistic trials remain sparse.

Read the full article on ESC Heart Failure.

Share with emailShare to FacebookShare to LinkedInShare to Twitter